RE: NASDAQ - Late Evening Update15 Feb 2019 04:27
We intend to request a meeting with the FDA, which typically should occur within approximately 30-45 days, to discuss the CRL. We look forward to working with the Agency to discuss options to advance iclaprim towards approval." ......... That 30-45 days is for the initial meeting just to discuss the reason. That could be followed my many months.